Revolutionizing Healthcare Together

Welcome to G Group Life Sciences: Catalyzing Breakthroughs in Healthcare

At G Group Life Sciences, we're driven by a singular, powerful purpose: to revolutionize healthcare and improve lives through groundbreaking scientific innovation. We believe the most profound advancements emerge at the intersection of cutting-edge research, unwavering dedication, and a deep understanding of complex biological systems. We're committed to fostering a culture of relentless curiosity and precision, where every breakthrough, no matter how small, contributes to a healthier future.

"

Our Unparalleled Expertise and Strategic Guidance

Our strength lies in the collective background of our team, providing us with an extraordinary ability to evaluate life science technology. This unique blend of experience also gives us the distinct capacity to articulate and represent your assets to both the scientific and capital markets communities.

Our team’s extensive experience isn't just theoretical; it's built on a foundation of real-world leadership and a deep understanding of the life sciences landscape. This includes:

• C-suite presence in both publicly traded and privately owned life science companies, offering an insider's perspective on industry challenges and opportunities.

• Many years of evaluating and representing drug and device candidates, encompassing a broad spectrum of innovations—whether diagnostic or therapeutic. We also have significant expertise in cutting-edge medical informatics technologies.

• A rich history in capital markets consultancy, successful capital raising initiatives, and strategic investor relations consultancy. This allows us to bridge the gap between scientific innovation and investment potential, ensuring your assets are compellingly presented to those who matter most.

Direct Capital Access and Proven Track Record

The G Group provides structured guidance and capital raising for both public and private emerging Life Science Companies. We understand the intricate journey from scientific discovery to market success, and we’re here to help you navigate every step.

When Required, Securities Offered Per FINRA requirements.. Our process also seamlessly integrates collaboration with other Investment Banks when appropriate, ensuring you have the best possible avenues for funding. Our team has a proven track record, having represented over 100 life science companies in a mix of retail and institutional investor-based raises.

A Specialized Team for Complex Challenges

The G Group team includes highly experienced investment bankers, an IP attorney, and seasoned industry, capital markets, and business development personnel. This diverse expertise ensures we provide comprehensive support tailored to your unique needs.

Our clients are primarily drug development, medical device, and medical informatics development companies, encompassing both public and private entities. We are committed to supporting innovators at every stage. We also pride ourselves on efficiency: extensive due diligence and market exposure material are completed rapidly and within the timeframe of engagement commitments pursuant to FINRA Bulletin 10-22.

Whether you're a potential partner, a brilliant mind seeking to join our team, or simply curious about the future of medicine, we invite you to explore our work. Discover how G Group Life Sciences is dedicated to transforming lives, one scientific advancement and strategic partnership at a time.

Our Leadership Team: Decades of Collective Expertise

At G Group Life Sciences, our strength is embodied by a leadership team with an unparalleled breadth and depth of experience across the entire life sciences ecosystem. Comprising seasoned investment bankers, legal experts, scientific innovators, and C-suite executives, our team possesses a unique vantage point—from early-stage R&D to successful market commercialization and capital deployment. We leverage this collective insight to provide our clients with strategic guidance, robust capital solutions, and a truly distinct competitive edge.

Robert J. Giordano: Founder & Visionary in Life Science Finance

With over 25 years dedicated to the life sciences and healthcare sectors, Bob Giordano has been instrumental in shaping the trajectories of nearly 100 companies. His extensive activities span capital market consultancy, investment banking, open market exposure, and sophisticated investor relations programs.

Bob's career began with a focus on consultancy, including a significant partnership at KSA, a prominent middle-market investor relations firm. This foundational experience transitioned into the investment banking realm, where he served as the Managing Director of Life Science Investment Banking at Jessup and Lamont, a venerable, century-old institution.

Most recently, Bob remains highly active as an investment banker at Network 1 Securities, primarily supporting IPO-ready life science companies. To better serve earlier-stage innovators, he maintains a principal association with The Giordano Group Inc. and Launchpad, Inc., leveraging their extensive funding contacts. This is complemented by an ongoing relationship with the esteemed Keiretsu Group.

His vast client portfolio overwhelmingly features drug development companies, medical device/med-tech companies, and diverse healthcare-related entities. The technologies his clients advance address a broad spectrum of critical indications, including cardiology, cancer, genetics, infectious disease, ophthalmology, orthopedics, HIV/AIDS, pain diagnosis and management, and CNS disorders.

Bob's ongoing activities include the rigorous evaluation of technology for its probability of gaining regulatory approval (and, for devices, the likelihood of market adoption), a deep assessment of company management's track record, competence, and presentation skills, and identifying the optimum pathways to capital raising. This includes discerning the most appropriate funding sources, the financial instruments to be utilized, and where crucial, strategic open market support for the company's growth.

Richard S. Serbin, ESQ.: Global Corporate Development & IP Strategist

Richard S. Serbin brings an exceptional combination of legal, pharmaceutical, and strategic corporate development expertise. Since May 2017, he has been the Head of Global Corporate Development at CURE Pharmaceutical Holding Corp., concurrently serving as President of Corporate Development and In-House Legal Counsel at Life Science Institute, LLC. As the founder of Radius Scientific Corporation, Mr. Serbin plays an active role in shaping business strategy, cultivating joint venture contacts, and guiding entities like Mazal Plant Pharmaceuticals Inc. in regulatory compliance and investor relations.

A global strategy advisor and entrepreneur, Mr. Serbin possesses dual credentials in pharmacy and law. This unique background is fortified by over 40 years of service as an FDA regulatory attorney and patent attorney within the healthcare industry. He is an acknowledged expert in licensing medical extracts, compounds, and technologies, bringing more than 25 years of pharmaceutical industry and investment community experience.

Mr. Serbin's distinguished career includes roles as Patent Attorney for Schering Plough Corporation and Chief FDA Counsel for Revlon Corporation and Johnson & Johnson Corporation. He dedicated a significant portion of his career to international markets and clients, serving in multiple capacities at Ortho Pharmaceuticals (a Johnson & Johnson subsidiary), Revlon, and Schering-Plough. Since September 2015, Mr. Serbin has been an influential Board Director for 16 U.S. and international subsidiary companies, including Ethicon, Ortho, J&J Consumer Products, Pittman-Moore, McNeil, and J&J Development Corporation. He has also served on the Scientific Advisory Board of Amazon Biotech, Inc., and for the last decade, has been a Senior Advisor to the prestigious Swedish American Life Science Summit (SALSS), held annually in Stockholm, Sweden.

Mr. Serbin holds a BS and B. Pharmacy from Rutgers University and Rutgers University College of Pharmacy, a J.D. degree from Seton Hall Law School, and a Master’s Degree in Trade Regulations and Law from NYU Law School.

Marcus F. Keep, MD: Neuroprotection Innovator & Scientific Advisor

Marcus Keep, MD, is a distinguished neurosurgeon and a pioneering founder in neuroprotection and rare mitochondrial diseases. He is a founder of NeuroVive Pharmaceutical (renamed Abliva), a publicly traded Swedish company on the Stockholm Nasdaq and the OTC market in the USA, where he served on the Board from 2000 to 2018.

Dr. Keep's collaboration with the Bob Giordano Group began in 2014, initially as a client where he successfully raised $8 million through a PIPE for NeuroVive. Subsequently, he transitioned to a pivotal role as a scientific and medical advisor to the Giordano Group, instrumental in evaluating and assisting early-stage technology companies.

Beyond his strategic advisory work, Dr. Keep is a practicing neurosurgeon specializing in neurotrauma at a Level 1 trauma center, with extensive experience in radiosurgery using Gamma Knife and CyberKnife. His medical training was conducted at the Montreal Neurological Institute, McGill University. He has also held academic positions as an assistant professor of neurosurgery at the University of New Mexico and an associate professor at Penn State Hershey.

Dr. Keep's neuroscience research background is equally impressive, including work on cerebellar transplantation at INSERM (the French NIH) in Paris. He also completed a two-year neuro-research fellowship at Lund University, Sweden, focusing on neuroprotection, brain plasticity, and epilepsy. His research extends to neuroprotection in amyotrophic lateral sclerosis, culminating in 27 peer-reviewed publications, 3 book chapters, and 4 patents.

John N. Bonfiglio, PhD, MBA: Biotech CEO & Turnaround Specialist

John N. Bonfiglio, PhD, MBA, brings over 30 years of extensive experience in the biotech and pharmaceutical industry, including more than two decades as a C-level executive in the biotech sector.

Dr. Bonfiglio began his career with 11 years at Allergan Pharmaceuticals, followed by three years at Baxter HealthCare. He then transitioned into the small biotech arena, quickly rising through the ranks. He notably achieved the position of CEO at Peregrine Pharmaceuticals, where he successfully turned around the financially strapped public company.

His executive leadership continued as COO at Cypress Bioscience during its reinvention as a neuro-pharmaceutical company. He then served as CEO at Immune Response Corporation, where he was responsible for raising over $50 million and restarting clinical programs in HIV and MS areas.

As CEO at Argos Therapeutics, a privately held oncology company, Dr. Bonfiglio successfully raised $35 million through a Series C financing. His tenure at Argos produced crucial clinical data that led to a successful IPO and subsequent financings.

Following Argos, he became President and CEO at Oragenics in Tampa, FL. Here, he orchestrated two strategic deals with Intrexon Corporation, raised $29 million, relisted the company on the NYSE:MKT, and strategically refocused the company on novel and proprietary antibiotics.

Most recently, Dr. Bonfiglio was COO at TapImmune, where he was responsible for initiating a clinical program, raising capital, and successfully relisting the company on Nasdaq. The company is now known as Marker Therapeutics (MRKR - Nasdaq).

Dr. Bonfiglio has also held independent Board positions at GT BioPharma (GTBP), Microlin, and Genprex (GNPX). He recently joined Sequella, a private company developing new therapies for Multi-Drug Resistant (MDR) diseases.

Bob Miller: CFO, Commercialization Expert & Capital Strategist

Bob Miller's career journey spans from investment banking at Merrill Lynch to serving as a CFO of a Fortune 500 company and Treasurer of a $4 billion enterprise. For the past two decades, Bob has dedicated his professional purpose to financing and commercializing unique medical technologies that demonstrably improve global health, leveraging his profound CFO skill sets to support healthcare companies.

For the last 20 years, Bob has served as the CFO of numerous healthcare companies, directly financing and assisting in the launch of groundbreaking medical technologies. A prime example is his early-stage involvement with Oculus (later renamed Sonoma Pharmaceuticals). He played a critical role in raising over $50 million privately from high-net-worth individuals to support both the FDA approval of a unique HOCL infectious disease technology (an antimicrobial without resistance and anti-inflammatory properties) and its approval and launch in Mexico. Sonoma Pharmaceuticals subsequently completed a successful IPO, receiving FDA approval in the United States and launching into the wound care, dermatology, and animal health markets. The use of HOCL has since become a standard of care in treating various wound care and dermatological diseases both domestically and internationally.

In 2014, Bob was promoted to the COO and CFO role at Sonoma, taking responsibility for critical functions including regulatory, clinical, reimbursement, manufacturing, finance, and investor relations. As a core member of the senior management team, Bob was intimately involved in the commercial launches into the wound care, dermatology, and animal health markets, driving significant success.

Robert J. Giordano

Richard S. Serbin, ESQ

Marcus F. Keep, MD

John N. Bonfiglio, PhD

Bob Miller

Representative Engagements: Medical Devices & Technology

We have a proven history of engagement with cutting-edge medical device and technology innovations, including:

• Advanced Cancer Diagnostics:

  • Breast Cancer: Utilizing electrical activity differentials and neural networking algorithms for non-invasive detection.

  • Breast Cancer: Employing spectrum of light technology to identify angiogenetic differentiation in lesions.

  • Melanoma & Related Cancers: Leveraging confocal microscopy to create virtual biopsies for early disease detection.

  • Autism & Mental Disorders: Utilizing MRI scans for objective, early diagnosis of autism spectrum disorders and identifying underlying physical causation for mental disorders to improve therapy outcomes.

• Targeted Therapeutics & Procedures:

  • Breast Cancer Therapeutics: Focus microwave-induced necrosis of cancerous lesions.

  • BPH Reduction: Focus microwave technology for ablation and necrosis of hyperplastic prostates.

  • Atrial Fibrillation: Utilizing laser technology for ablation procedures.

  • Post-Surgical Anastomosis: Employing radiofrequency heating of collagen as an alternative to surgical stapling.

  • Vulnerable Plaque: Utilizing Raman spectroscopy for non-invasive analysis and follow-on treatment of vulnerable plaque.

• Surgical Innovation & Patient Care:

  • Surgical Fluid Removal: Development of a continuous in-wall plumbing system for operating rooms, replacing traditional fluid bottles.

  • Brain Surgery Hypothermia: Unique intubated internal cooling fluids to induce hypothermia, preventing unintended blood clots and dispersed neural apoptosis during brain surgery.

• Diagnostic & Healing Technologies:

  • Pain Diagnosis & Management: Utilizing brain scans to identify and quantify the specific impact of pain medication.

  • Accelerated Healing & Scaffolding: Utilizing unique polymers with controllable variable rates of hardening for enhanced healing and body part scaffolding.

  • Enhanced Ultrasound Technology: Efforts to enhance ultrasound's ability to penetrate bone and surgically deposited solid matter.

  • Diabetes Diagnostics: Utilization of wired enzyme technology for glucose extraction without finger-sticking or blood draws, designed for insurance adoption.

  • Sudden Coronary Death Syndrome (SCD): Development of algorithms to analyze the competitive interaction of the brain and heart's electrical signaling as causative factors.

• Medical Informatics & Wellness:

  • Insurance Wellness Programs: Algorithm-based analysis of claims history to target insureds experiencing initial onset of diabetes-related diseases, aiming to reduce costs.

Strategic Engagements & Capital Market Success

Our team's direct involvement in orchestrating successful capital raises and strategic initiatives underscores our capability to bridge the gap between scientific innovation and market value.

The Children's Hospital of Los Angeles (CHLA) Engagement

We undertook an ongoing, nearly two-year engagement with the CHLA incubator/tech transfer department. During this period, our team meticulously evaluated over 40 early-stage pediatric assets in both device and drug development. Our assessment focused on crucial elements such as the presence or absence of a real unmet need (and thus, the probability of adoption), the appropriateness and adequacy of the claimed FDA pathway, and the overall presentation skills of the project sponsors. Following this evaluation, we received a follow-on mandate to assist each identified worthwhile asset in its funding efforts.

Selective Banking Transactions (Led or Co-Led by Robert J. Giordano)

Our track record includes direct leadership in significant capital raising events for a diverse portfolio of companies:

• Neurovive (NEVPF) / Abliva: (Initiated and led banker) Utilized a mitochondrial-based approach for stopping secondary apoptosis in cardiac ischemia and TBI with low-dose repurposed cyclosporine. When publicly traded on the Junior Swedish Bourse, we advised on U.S. fundraising without a U.S. listing. We organized meetings with 11 potential co-bankers, selected one, and successfully raised $8.5 million through institutional investors, followed by an additional $1+ million from a NYC family office. Bob recommended David Laskow Pooley to their board, where he remains Chairman. Marcus Keep, MD, a co-founder of Neurovive, now serves as a key scientific advisor to G Group Life Sciences.

• GENPREX (GNXP): (Co-initiated and led banker) Focused on non-small cell lung cancer using a lipid delivery system encapsulating a gene delivery mechanism to replace a defective Tus-2 gene, combined with an immune-based therapeutic agent inducing apoptosis. We introduced the then-private company to our retail network and other potential co-bankers (including Noble), raising approximately $5 million through our retail system before completing an IPO that raised an additional $5+ million. Bob extensively collaborated with Julian Pham, MD, and CEO Rodney Varner to refine their presentation for all prospective investors.

• TapImmune (now Marker Therapeutics, MRKR): (Initiated and led banker) This company possessed an immune-based anti-cancer therapy designed to upregulate both CD4 and CD8 cells. As a struggling public company on the bulletin board, we negotiated the termination of a prior engagement and successfully completed a series of initial banking transactions, including the subsequent conversion of warrants, totaling approximately $20+ million, in conjunction with Rodman & Renshaw/Wainwright and our retail system. Bob recommended David Laskow Pooley to the board, where he continues to serve, and was part of the process that led to the company's NASDAQ uplisting.

• Lucid Technologies: (Initiated and led banker) Developed a non-invasive melanoma diagnostic device using confocal microscopy for electronic transmission of morphological samples for pathology analysis. We raised capital through our retail system and then took the company public on NASDAQ, raising approximately $15 million in total. (The company later reverted to private ownership.)

• Protea, Inc.: (Initiated and led banker) Developed laser-based technology for sample ablation, allowing direct introduction into mass spectroscopy without traditional well-plate chemical manipulation. We raised approximately $5 million through our retail system, then took the company public on NASDAQ, raising an additional $7 million.

• HyreCar (HYRE): (Initiated and led banker - non-life science) This private company developed a platform connecting drivers for Uber/Lyft without personal cars to available vehicles. We raised approximately $5 million through our retail system, then successfully completed a NASDAQ IPO, raising an additional $12 million. (This engagement was undertaken due to a personal family connection).

• Oragenics (OGEN): (Initiated and led banker for our firm) When engaged, this public OTC company was seeking an uplisting to a major exchange and developing a novel "lantibiotic" to address drug-resistant antibiotic problems. We assisted Griffin Securities in a capital raise of approximately $20 million and a listing on the AMEX. John Bonfiglio was the CEO at the time and remains a key member of our scientific efficacy evaluation group.

• Consortium Management - CFSG: (Initiated and led banker) This public company developed an Radio Frequency (RF) generator-based technology to complete end-to-end gastric anastomosis as a substitute for standard surgical stapling. We raised approximately $5 million through our retail system, then uplisted the company on the AMEX, raising an additional $5 million. (The company subsequently ceased operations; its assets were acquired privately, and a re-introduction as a public company is possible, in which Bob may be involved.)

• Biodrain: (Initiated and led banker) This private company developed an alternative system for removing body fluids created during surgical procedures in the OR. We raised approximately $5+ million as a private company through our retail system, and the company was ultimately acquired by a competitor.

• Immune Response Corporation: (Capital markets and IR consultant for over two years) This public company was co-founded by Kevin Kimberlin of Spencer Trask and Jonas Salk. Bob organized and executed deal and non-deal roadshows nationwide, resulting in the stock increasing from $0.25 to $3.00. He introduced the company to Michael Vasinkovich (then of Rodman & Renshaw), who subsequently raised approximately $15 million for the company. During this period, Bob worked closely with two CEOs, including John Bonfiglio (mentioned above) and Joseph O’Neill MD (creator of the PEPFAR initiative), both suitable references.

• Naked Brands: (Non-life science public company) Focused on unique men's and women's underwear and sleepwear. Bob served as a capital markets consultant and, leveraging a personal connection, introduced David Hochman's mother (a leader in women's intimate apparel) to CEO Joel Primus. She ultimately became the company's chairman. David Hochman and Joel Primus are suitable references.

• Biofield: (Initiated and led banker) This public company developed a diagnostic alternative to mammograms, using the discernible difference in electrical energy/activity between cancerous and non-cancerous breast cells. We participated in raises of approximately $8-$10 million in several transactions. The company ultimately ceased operations after the FDA required a PMA approval (rather than a 510K device clearance) and expressed discomfort with the neural networking approach of their software.

Contact Us

Get in touch for innovative financial consulting in biotech.